MX346878B - Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo. - Google Patents

Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo.

Info

Publication number
MX346878B
MX346878B MX2013007474A MX2013007474A MX346878B MX 346878 B MX346878 B MX 346878B MX 2013007474 A MX2013007474 A MX 2013007474A MX 2013007474 A MX2013007474 A MX 2013007474A MX 346878 B MX346878 B MX 346878B
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
ctld
seq
domain
pig
Prior art date
Application number
MX2013007474A
Other languages
English (en)
Other versions
MX2013007474A (es
Inventor
Domingos Possani Postay Lourival
Olvera Rodríguez Alejandro
Martha Pedraza Escalona María
Pavel Espino Solis Gerardo
Miguel Cardoso Torres Héctor
Original Assignee
Univ Nac Autónoma De México
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nac Autónoma De México filed Critical Univ Nac Autónoma De México
Priority to MX2013007474A priority Critical patent/MX346878B/es
Priority to US14/898,037 priority patent/US9951135B2/en
Priority to PCT/MX2014/000093 priority patent/WO2014209096A1/es
Publication of MX2013007474A publication Critical patent/MX2013007474A/es
Publication of MX346878B publication Critical patent/MX346878B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6833—Viral toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención se refiere a un anticuerpo que reconoce el dominio CTLD-2 del receptor celular DEC-205 de Gallus gallus (SEQ ID NO: 1), caracterizado porque comprende un fragmento VH con la secuencia de aminoácidos SEQ ID NO: 15 y un fragmento VL con la secuencia de aminoácidos SEQ ID NO: 13.
MX2013007474A 2013-06-26 2013-06-26 Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo. MX346878B (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2013007474A MX346878B (es) 2013-06-26 2013-06-26 Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo.
US14/898,037 US9951135B2 (en) 2013-06-26 2014-06-17 Monoclonal antibodies against the DEC-205 receptor of chicken dendritic cells
PCT/MX2014/000093 WO2014209096A1 (es) 2013-06-26 2014-06-17 Nuevos anticuerpos monoclonales contra el receptor dec-205 de células dendríticas de pollo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013007474A MX346878B (es) 2013-06-26 2013-06-26 Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo.

Publications (2)

Publication Number Publication Date
MX2013007474A MX2013007474A (es) 2014-12-26
MX346878B true MX346878B (es) 2017-03-28

Family

ID=52142329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007474A MX346878B (es) 2013-06-26 2013-06-26 Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo.

Country Status (3)

Country Link
US (1) US9951135B2 (es)
MX (1) MX346878B (es)
WO (1) WO2014209096A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061576B (zh) * 2015-08-11 2018-05-29 集美大学 大黄鱼C凝集素Nattectin基因及其重组蛋白和应用
CN110540579B (zh) * 2018-05-29 2022-09-06 普莱柯生物工程股份有限公司 一种副鸡禽杆菌抗原蛋白、含有副鸡禽杆菌抗原的疫苗组合物、及其制备方法和应用
WO2023070317A1 (zh) * 2021-10-26 2023-05-04 江苏省农业科学院 基于dc细胞的双功能纳米抗体及其构建方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258688A1 (en) 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
AU2002953223A0 (en) * 2002-12-06 2003-01-02 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Novel therapeutic molecules and uses thereof
US20090130109A1 (en) 2002-12-06 2009-05-21 Derek Nigel John Hart DCL-1 and uses thereof
NZ585556A (en) 2007-11-07 2012-07-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2011044452A2 (en) 2009-10-08 2011-04-14 President And Fellows Of Harvard College Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences

Also Published As

Publication number Publication date
MX2013007474A (es) 2014-12-26
US9951135B2 (en) 2018-04-24
US20160347841A1 (en) 2016-12-01
WO2014209096A1 (es) 2014-12-31

Similar Documents

Publication Publication Date Title
CO2019013614A2 (es) Dominio de unión a antígeno
Deliyannis et al. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge
EA202191939A1 (ru) Химерные антигенные рецепторы gprc5d и экспрессирующие их клетки
Grodeland et al. Antigen targeting to human HLA class II molecules increases efficacy of DNA vaccination
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
MX2021006239A (es) Receptores quimericos de antigeno que tienen como diana a cd-19.
FI3736291T3 (fi) Anti-fcrh5-vasta-aineita
EA201790280A1 (ru) Ror1-(ntrkr1)-специфические химерные антигенные рецепторы для иммунотерапии рака
NZ725079A (en) Transgene genetic tags and methods of use
EA201891459A1 (ru) Новое поколение антигенспецифических tcr
RU2011144089A (ru) Композиции вакцин и способы их применения
JP2018503600A (ja) グリカン相互作用化合物及び使用方法
RU2017112884A (ru) Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
MX2019015286A (es) Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias.
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
MX2013007474A (es) Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo.
CL2019003423A1 (es) Nuevos péptidos (seq id n°378), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
Iankov et al. Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens
UY37752A (es) Proteínas de unión al antígeno anti-jagged1
MX2021012488A (es) Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos.
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
BR112018014250A2 (pt) roedor, célula ou tecido isolados de roedor, célula imortalizada, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor e de um anticorpo
Li et al. Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies
Tamura et al. Production of antibodies against multipass membrane proteins expressed in human tumor cells using dendritic cell immunization

Legal Events

Date Code Title Description
FG Grant or registration